Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumours
despite the use of multi-agent conventional chemotherapy regimens. Such poor outcomes …

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal malignancies and is
characterized by a unique tumor microenvironment (TME) consisting of an abundant stromal …

Pancreatic ductal adenocarcinoma (PDAC) is composed of a minority of malignant cells
within a microenvironment of extracellular matrix, fibroblasts, endothelial cells, and immune …

Pancreatic ductal adenocarcinoma (PDAC) is increasing in incidence and is projected to
become the second leading cause of cancer death in the United States. Despite significant …

Simple Summary There is currently no effective treatment for Pancreatic Ductal
Adenocarcinoma (PDAC), and it is still the deadliest cancer, despite great research efforts in …

Pancreatic ductal adenocarcinoma (PDA) is a common and lethal malignancy resulting in
more than 250,000 deaths per year worldwide. Despite extensive efforts, cytotoxic and …

Pancreatic ductal adenocarcinoma (PDA) is notoriously aggressive and hard to treat. The
tumour microenvironment (TME) in PDA is highly dynamic and has been found to promote …

Pancreatic ductal adenocarcinoma is a stroma-rich and highly challenging cancer to treat.
Over recent years, it has become increasingly evident that the complex network of soluble …

Pancreatic ductal adenocarcinoma (PDAC) features a prominent stromal microenvironment
with remarkable cellular and spatial heterogeneity that meaningfully impacts disease …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor
immune microenvironment (TIME) formed by interactions among cancer cells, immune cells …